Format

Send to

Choose Destination
J Med Chem. 2012 Apr 26;55(8):3739-55. doi: 10.1021/jm201608g. Epub 2012 Apr 6.

Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis.

Author information

1
Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee, 881 Madison, Memphis, Tennessee 38163, USA.

Abstract

Aurachin RE (1) is a strong antibiotic that was recently found to possess 1,4-dihydroxy-2-naphthoate prenyltransferase (MenA) and bacterial electron transport inhibitory activities. Aurachin RE is the only molecule in a series of aurachin natural products that has the chiral center in the alkyl side chain at C9'-position. To identify selective MenA inhibitors against Mycobacterium tuberculosis , a series of chiral molecules were designed based on the structures of previously identified MenA inhibitors and 1. The synthesized molecules were evaluated in in vitro assays, including MenA enzyme and bacterial growth inhibitory assays. We could identify novel MenA inhibitors that showed significant increase in potency of killing nonreplicating M. tuberculosis in the low oxygen recovery assay (LORA) without inhibiting other Gram-positive bacterial growth even at high concentrations. The MenA inhibitors reported here are useful new pharmacophores for the development of selective antimycobacterial agents with strong activity against nonreplicating M. tuberculosis.

PMID:
22449052
PMCID:
PMC3375340
DOI:
10.1021/jm201608g
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center